Inventiva Logo

Inventiva

Clinical-stage biopharma developing oral therapies for fibrosis, oncology, & lysosomal disorders.

IVA | PA

Overview

Corporate Details

ISIN(s):
FR0013233012 (+2 more)
LEI:
969500I9Y690B3FZW590
Country:
France
Address:
50 RUE DE DIJON, 21121 DAIX
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Inventiva is a clinical-stage biopharmaceutical company focused on the development of novel oral small molecule therapies for diseases with significant unmet medical needs. The company's primary therapeutic areas include fibrosis, lysosomal storage disorders, and oncology. Its lead drug candidate, lanifibranor, is in a pivotal Phase III clinical trial for the treatment of non-alcoholic steatohepatitis (NASH) and has received Breakthrough Therapy Designation from the FDA. Another clinical candidate, odiparcil, targets mucopolysaccharidoses (MPS). Inventiva's pipeline is supported by a proprietary discovery engine with an extensive library of 240,000 compounds, a wholly-owned R&D facility, and expertise in targeting nuclear receptors and transcription factors.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-28 15:56
Regulatory News Service
Franchissement de seuils
French 120.1 KB
2025-11-28 15:42
Major Shareholding Notification
Franchissement de seuils
French 121.1 KB
2025-11-28 15:25
Major Shareholding Notification
Franchissement de seuils
French 110.0 KB
2025-11-13 15:21
ISS
Inventiva annonce les modalités définitives ainsi que l'extension de l'offre au…
French 353.4 KB
2025-11-13 15:21
ISS
Inventiva announces pricing of upsized public offering of approximately $150M o…
English 349.5 KB
2025-09-29 00:00
Interim Report
RFS
French 927.7 KB
2025-08-25 09:57
Major Shareholding Notification
Franchissement de seuil
French 114.0 KB
2025-08-25 09:56
Major Shareholding Notification
Franchissement de seuil
French 112.0 KB
2025-08-19 15:35
Major Shareholding Notification
Franchissement de seuil
French 116.8 KB
2025-08-19 15:32
Major Shareholding Notification
Franchissement de seuil
French 116.7 KB
2025-08-19 15:19
Major Shareholding Notification
Franchissement de seuil
French 116.1 KB
2025-08-12 15:57
Major Shareholding Notification
Franchissement de seuil
French 113.9 KB
2025-08-12 15:52
Major Shareholding Notification
Franchissements de seuil
French 121.6 KB
2025-08-11 15:14
Major Shareholding Notification
Franchissement de seuil
French 121.9 KB
2025-06-17 17:02
Major Shareholding Notification
Franchissement de seuils
French 113.4 KB

Automate Your Workflow. Get a real-time feed of all Inventiva filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Inventiva

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Inventiva via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-04-05 N/A Other Buy 10,000 N/A
2023-12-08 N/A Other Buy 15,000 N/A

Peer Companies

Nuvectis Pharma, Inc. Logo
Clinical-stage biopharma developing precision medicines for serious oncological conditions.
United States of America
NVCT
Nykode Therapeutics ASA Logo
Developing novel immunotherapies and vaccines for cancer with its antigen-targeting platform.
Norway
NYKD
Ocugen, Inc. Logo
Develops gene/cell therapies and vaccines, specializing in blindness and public health.
United States of America
OCGN
Oculis Holding AG Logo
Clinical-stage biopharma developing non-invasive eye drops for sight-threatening diseases.
Switzerland
OCS
OKYO Pharma Ltd Logo
Biopharma developing novel drugs for inflammatory eye diseases and neuropathic corneal pain.
United States of America
OKYO
OLIPASS CORPORATION Logo
Biotech firm developing RNA therapeutics for diseases with its proprietary OPNA platform.
South Korea
244460
A technology platform for pharma/biotech to discover therapeutic antibodies via transgenic animals.
United States of America
OABIW
Oncocross Co.,Ltd. Logo
AI-powered biotech accelerating drug development for cancer and rare diseases.
South Korea
382150
Onconic Therapeutics Inc. Logo
Develops novel drugs for cancer and GI diseases, including a next-gen acid blocker.
South Korea
476060
OncoTherapy Science, Inc. Logo
Develops targeted cancer therapies and provides TCR repertoire analysis services.
Japan
4564

Talk to a Data Expert

Have a question? We'll get back to you promptly.